Showing results (11-20 of 164) with videos related to
Sort By:
Pageof 17
Diabetes Technology & Therapeutics|February 14, 2006
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitusAndreas Pfützner, Thomas ForstExpert Review of Endocrinology & Metabolism|February 9, 2019
Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitusThomas Forst, Andreas PfütznerJournal of Diabetes Science and Technology|July 5, 2011
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazoneAndreas Pfützner, Thomas ForstExpert Opinion on Pharmacotherapy|December 14, 2011
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetesThomas Forst, Andreas PfütznerExpert Review of Endocrinology & Metabolism|February 13, 2019
Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitusThomas Forst, Andreas PfütznerExpert Opinion on Drug Delivery|November 22, 2005
Pulmonary insulin delivery by means of the Technosphere drug carrier mechanismAndreas Pfützner, Thomas ForstExpert Opinion on Pharmacotherapy|March 1, 2006
Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortalityAndreas Pfützner, Thomas ForstExpert Opinion on Pharmacotherapy|October 4, 2013
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitusThomas Forst, Andreas PfütznerExpert Review of Medical Devices|July 30, 2024
The crucial role of fecal management systems in intensive careTobias Gutting, Andreas PfütznerExpert Opinion on Pharmacotherapy|June 7, 2011
Review of approved pioglitazone combinations for type 2 diabetesThomas Forst, Markolf Hanefeld, Andreas PfütznerPageof 17